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population breakdown, survival rates, average costs of triple and quadruple HAART 
(Highly Active Antiretroviral Therapy) therapy, inpatient, outpatient care costs—HIV 
related HRG costs and excess cost ratio due to late presentation. Study follows stan-
dard good modeling practices by discounting, adjusting for survival, and considering 
multiple time horizons for analyses. UK data sources include: BHIVA, NHS, HPA and 
SOPHID. RESULTS: From 1995–2010 literature review yielded 126 publications 
related to late detection, of which 18 were included in our study design. The number 
of publications has rapidly increased over the last 12 months. Preliminary results 
suggest that 10% of HIV detection shift from late to early detection (2655 patients 
or 3.2% of Late HIV detection) would result in £20.3 million conservative savings 
just in the ﬁ rst year (keeping index multiplier scalar for HIV spread rate at zero). Over 
5-year term, such annual shift would result in 708.25 life-years saved or £14.2 million 
in additional savings. CONCLUSIONS: Enhanced testing to achieve earlier detection 
and initiation on HAART could potentially reduce overall costs of HIV medical care. 
Further research is required to determine additional budgetary implications of HIV 
comorbidity patterns.
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OBJECTIVES: Human papillomavirus (HPV) has been implicated as a causal factor 
in cervical cancer (CC), the second most common cancer among women worldwide. 
Prophylactic vaccination against HPV-16/18 has been shown to be highly effective in 
preventing HPV related infections and pre-cancerous lesions. The aim of this study 
was to determine the potential clinical and economic impact of combining CC screen-
ing programme with HPV vaccination programme with the bivalent HPV-16/18 
vaccine in women aged 25 (when CC screening starts) compared to screening alone. 
METHODS: A Markov cohort model was adapted to the Italian setting. The model 
replicates the HPV infection natural history leading to CC and includes the effect of 
screening and vaccination. Based on the latest results of the PATRICIA clinical trial 
for the bivalent vaccine, the vaccine efﬁ cacy includes cross-protection against non-
vaccine HPV types 31/33/35/39/45/51/52/56/58/59. The vaccine efﬁ cacy in naïve girls 
and HPV-exposed women (>17-years old) was differentiated. Lifetime protection and 
90% vaccination coverage were assumed. Costing was analyzed from the perspective 
of the Italian health care system. Main outcomes are lifetime costs, QALYs, CC cases, 
deaths and ICER. Both costs and effects were discounted at 3% annually to calculate 
the ICER. RESULTS: The model shows that, compared to screening alone, vaccinating 
a single cohort of 330,000 women aged 25 would prevent over a lifetime 696 CC 
cases and 316 CC deaths (undiscounted) of which 131 and 59 respectively are due to 
cross-protection, with a discounted ICER of c33,918 per QALY gained. The ICER 
remains under the cost-effective threshold deﬁ ned by the WHO (between 1 and 
3xGDP/capita). CONCLUSIONS: Under the assumptions of the model, extending 
vaccination to young adult women post-HPV exposure could lead to a substantial 
reduction in CC and remains cost-effective in Italy compared with screening alone. 
Cross-protection would play an important role in this reduction.
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OBJECTIVES: Rotavirus is the leading cause of severe gastroenteritis in children under 
5 years. Two vaccines are currently available: RotaTeq® (Merck/Sanoﬁ  Pasteur MSD) 
and Rotarix® (GSK). Published economic models on rotavirus vaccination have pro-
duced contradicting results. We reviewed and critically appraised existing economic 
models. METHODS: The literature search covered worldwide cost-effectiveness 
models of RotaTeq® and Rotarix® published or presented at conferences until 
October 2009. We extracted information on model structures, input data (epidemiol-
ogy, vaccine efﬁ cacy, utilities, vaccination costs) and results. RESULTS: We identiﬁ ed 
44 publications referring to distinct cost-effectiveness analyses.18 used cost per QALY 
as primary outcome, providing 22 incremental cost-utility ratios (ICURs) for high-
income countries. Thirteen ICURs came from health authorities and 9 from manufac-
turers. While some European studies predicted cost-savings from societal perspective, 
the ICUR was estimated at up c160,000 per QALY for the UK, from NHS perspective. 
5 of 13 analyses from health authorities reported ICURs below c30,000 per QALY 
gained, compared to 7 of 9 studies from manufacturers. There were many differences 
between models, such as perspective, epidemiological inputs, vaccine efﬁ cacy and 
vaccination costs. However differences in results were mainly driven by assumptions 
related to estimation of QALYs: utility values, duration of symptoms, inclusion of 
quality of life burden for caregivers and for cases without medical attention. CON-
CLUSIONS: Results of cost-effectiveness analyses are highly variable due to uncer-
tainty surrounding epidemiological inputs, and most importantly to assumptions for 
deriving QALYs. Different choices were attributable to different value judgments, and 
to the difﬁ culty of measuring and valuing quality of life in children, which lead to a 
situation where neither manufacturers nor health authorities obtained valid utilities. 
There is currently no valid reference case for cost-utility analyses in paediatrics. More 
open communication and expertise sharing between authorities and manufacturers 
could lead to more reliable analyses.
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OBJECTIVES: Streptococcus pneumonia is associated with two invasive diseases 
(meningitis and bacteremia) and non-invasive disease (pneumococcal pneumonia), 
which has caused high morbidity and mortality in infants and the elderly in Taiwan. 
a cost-effectiveness analysis of pneumococcal conjugate vaccine (PCV 10) in Taiwan 
was conducted using transmission-dynamic model. METHODS: As static pharmaco-
economic model fails to account for vaccination-induced herd-immunity, we devel-
oped an age-structured multi-compartment dynamic model to estimate both economic 
and clinical impact of universal PCV10 vaccination over 10-year time horizon under 
health care system’s perspective in Taiwan. Model parameters such as economic and 
clinical burden of pneumococcal diseases in Taiwanese population, vaccine efﬁ cacy, 
utilities and demographic parameters were captured by retrospective population-based 
National Health Insurance Reimbursement Database (NHIRD), published sources, 
unpublished data, and assumptions made in consultation with clinical experts. Uni-
variate sensitivity analyses were conducted to test the robustness of model parameters. 
RESULTS: Assuming a four-dose schedule and 90% of vaccination coverage for both 
vaccines, universal infant vaccination with PCV10 would prevent 133 cases of IPD, 
122,476 cases of pneumococcal pneumonia and 3,857 deaths, an equivalent of 93,393 
life-years and leads to a net medical cost savings of NT$ 6,047.4 million, compared 
to no vaccination. At the current proposed price of NT$2,700 for PCV10, the incre-
mental cost-effectiveness ratio (ICER) is expected to be cost-effective with NT$106,362 
(US$3,324) per life-year gained. The program’s cost-effectiveness results are highly 
sensitive to the vaccine price and number of doses while not sensitive to uncertainty 
in disease incidence and costs of treatment. CONCLUSIONS: Universal pediatric 
PCV10 vaccination in Taiwan is estimated to have considerable impact on reducing 
the burden of pneumococcal diseases and expected to be cost-effective in payer’s 
perspective compared to no vaccination.
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OBJECTIVES: To assess the efﬁ ciency of daptomycin as ﬁ rst-line therapy (D) versus 
daptomycin as rescue therapy after failure of vancomycin (V+D) or linezolid (L+D) in 
gram-positive bacteremia treatment. METHODS: A cost-effectiveness analysis com-
paring the three therapeutic alternatives (D, V+D and L+D) was performed using data 
from a previous observational study (EUCORE). In the present sub-study, data on 19 
(D), 33 (V+D) and 19 (L+D) bacteremic patients were analyzed. Effectiveness was 
measured in terms of cure or clinical improvement. Costs were gathered from “BOT” 
and “e-salud” Spanish databases. Direct costs (medication and hospitalization) due to 
bacteremia were included. Costs are expressed in 2009 Euros. Patients were observed 
until either end of daptomycin therapy or exitus. a probabilistic multivariate sensitivity 
analysis was carried out. Dispersion was estimated using bootstrap (three alternative 
scenarios were considered in the simulations: 50%, 25% and 10% of the estimated 
dispersion) and Monte Carlo simulations were performed for both costs (log-normally 
distributed) and effectiveness (normally distributed) measures. RESULTS: Effective-
ness ﬁ gures: D: 84.2% (95%CI: 60.4%–96.6%); V+D: 87.9% (95%CI: 71.8%–
96.6%); L+D: 68.4% (95% CI: 43.5%–87.4%); pvalue = 0.206 (Chi2). Average costs 
per treated patient: D: c6672.8 (95%CI: 4076.8–9268.8); V+D: c9786.6 (95%CI: 
7,124.7–12,448.5); L+D: c12,190.4 (95%CI: 8,693.2–15,687.7); pvalue < 0.001 
(Kruskal-Wallis). Cost-Effectiveness Incremental Ratios: c53,478.8 (D versus V+D) 
and −c6,639.5 (D versus L+D) per additional cured patient. Sensitivity analysis results: 
D versus V+D: D is efﬁ cient with lower costs (in 41.2%–77.9% of the simulations) 
and dominant (22.1%–38.0%); D versus L+D: D is dominant (44.6%–99.6%) and 
efﬁ cient with lower costs (0.4%–30.0%). CONCLUSIONS: Daptomycin as ﬁ rst-line 
therapy is mainly a dominant alternative when compared to daptomycin as rescue 
therapy after linezolid failure, showing better clinical results with lower associated 
costs. Daptomycin as ﬁ rst-line therapy does not show signiﬁ cant differences in effec-
tiveness when compared to daptomycin as rescue therapy after vancomycin failure, 
but it shows signiﬁ cantly lower costs.
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OBJECTIVES: Vaccination with the 23-valent pneumococcal polysaccharide vaccine 
(PPV23) is the current standard in Germany for diagnosis deﬁ ned risk groups (age 
5–59 years) and for seniors (≥60 years). a redeﬁ nition of this recommendation 
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following market authorization of the 13-valent pneumococcal conjugate vaccine 
(PCV13) for adults might be considered. Thus, this study analyzes potential cost-
effectiveness of an adult vaccination with PCV13 from the point of view of the German 
social health insurance. METHODS: In a cross-sectional steady state Markov model, 
efﬁ cacies of the vaccines on invasive pneumococcal diseases (IPD), and community-
acquired pneumonia (CAP, treated in either a hospital or a nonhospital setting) were 
calculated. a steady state is deﬁ ned as a setting in which the whole population (includ-
ing new entrants) is vaccinated as recommended. The modeling of PPV23 and PCV13 
distinguished between risk groups and both vaccines were compared to non-vaccina-
tion. Data on PCV13 were derived from published results on the 7-valent pneumococ-
cal conjugate vaccine (PCV7). The effectiveness of individual pneumococcal 
vaccination of adults was adjusted for expected herd immunity effects of a pediatric 
vaccination with PCV. Utilization of health care services and unit costs were taken 
from publicly accessible data bases. RESULTS: Compared to PPV23, PCV13 revealed 
the potential to avoid a greater number of yearly cases and deaths due to IPD and 
CAP in Germany. For PCV13 it can be expected that monetary savings, resulting e.g. 
from less hospitalization, compensate the costs of the vaccination program. The 
preliminary version of the model concludes that the cost-beneﬁ t ratio is 1.16, i. e. c1 
spend on vaccination saves c1.16 treatment cost. CONCLUSIONS: Our model shows 
that the health economic beneﬁ t of an immunization of adults with PCV13 can be 
expected to be higher than that of PPV23.
PIN32
ECONOMIC IMPACT OF THE 10-VALENT PNEUMOCOCCAL NON-
TYPEABLE HEMOPHILUS INFLUENZAE PROTEIN D CONJUGATE 
VACCINE (PHID-CV) IN A COHORT OF NEWBORN IN HONG KONG
Lee KK1, Hon EK2, Lee VW2, So TM3, Chow DP2
1Monash University Kuala Lumpur Sunway Campus, Selangor Darul Ehsan, Malaysia; 2Chinese 
University of Hong Kong, Hong Kong, China; 3Princess Margaret Hospital, Hong Kong, China
OBJECTIVES: To examine the health and economic impact of PHiD-CV in the public 
sector of Hong Kong compared to no vaccination. METHODS: A Markov analytical 
model modiﬁ ed from the recent Cost-effectiveness Cohort Model for Synﬂ orix (COSY 
Model by HE-group, GCRD, GSK bio, Wavre, Belgium, 2010) was used for the 
analysis of the outcomes of vaccination. The cohort model simulates in a birth cohort 
of 82,100 newborns the disease process of invasive disease (ID) (meningitis and 
bacteremia), community acquired pneumonia (CAP), and acute otitis media (AOM) 
over life-time caused by S pneumoniae and Non-typeable H inﬂ uenzae (NTHi) within 
‘monthly’ cycles. Superimposed on the disease process is integrated in the model its 
disease management expressed in hospitalization rates, medical visits, and speciﬁ c 
interventions such as myringotomies. The epidemiology and disease management is 
Hong Kong speciﬁ c. The study was performed from a health care payer’s perspective. 
RESULTS: The study shows for a 4-dose regimen of PHiD-CV compared to no vac-
cination over a period of 100 years: a gain of 234 quality-adjusted-life-years (QALY); 
an avoidance of 16 cases of IPD, 873 cases of pneumonia, 26,746 cases of AOM and 
25,885 sequelae. Using a 5% discount for cost and beneﬁ ts, cost/QALY gained was 
estimated to be HKD261,492. CONCLUSIONS: With GDP per capita of Hong Kong 
being HKD233,060 in 2009, our study results suggest PHiD-CV vaccination is cost-
effective in providing protection to the people of Hong Kong based on the WHO 
recommended thresholds for cost-effectiveness.
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OBJECTIVES: To evaluate cost-effectiveness of routine pneumococcal vaccination 
with 10-valent pneumococcal non-typeable Haemophilus inﬂ uenzae protein-D vaccine 
(PHiD-CV) compared with 13-valent pneumococcal conjugate vaccine (PCV-13) and 
no vaccination. METHODS: A Markov cohort model with a 100-year time horizon 
was developed to project the impact of vaccination on the incidence of pneumococcal 
and non-typeable Haemophilus Inﬂ uenzae (NTHi) infections in children and adults. 
Data Sources: Czech Republic-speciﬁ c epidemiological and demographic data and data 
from other country sources. Base-case assumptions include estimates of pneumococcal 
and NTHi infection rates as well as vaccine efﬁ cacy based on published literature. 
Model inputs: payer perspective, 80% vaccine coverage, no herd protection and a (3 
+ 1) vaccination schedule. One-way sensitivity analyses performed to assess the impact 
of changes in key model assumptions. RESULTS: PHiD-CV and PCV-13 are projected 
to prevent more cases of invasive disease (89 and 92 respectively) and pneumonia 
hospitalizations (738 and 760 respectively) compared with no vaccination. PHiD-CV 
and PCV-13 are projected to prevent additional GPP/ENT visits due to acute otitis 
media (AOM) (7851 and 3838 respectively) compared with no vaccination strategy. 
The total number of cases of invasive disease was comparable for both vaccines but 
PHiD-CV is estimated to prevent more than 14 000 cases of AOM in comparison 
with PCV-13. Vaccinating a birth cohort with PHiD-CV is expected to generate 75.5 
more QALYs and 5.9 LYG compared to PCV-13. Under vaccine price parity assump-
tions, estimated total savings for health care system are 10.2 mil CZK or 395.6 k EUR 
for PHiD-CV compared to PCV-13 respectively. Sensitivity analyses indicate that 
AOM efﬁ cacy and incidence of AOM related GPP/ENT visits have biggest impact on 
results. CONCLUSIONS: Overall, PHiD-CV is expected to have better quality of life 
impact than PCV-13. Under price parity assumptions, PHiD-CV dominates PCV-13 
because it also has a larger cost offsets.
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OBJECTIVES: In contrast to commonly used discrete-time Markov models, we devel-
oped a more realistic continuous-time multi-stage Markov model to evaluate long-term 
clinical and economic outcomes of raltegravir in treatment naïve HIV-1 patients. 
METHODS: The multi-stage cost-effectiveness model incorporating 3 lines of therapy 
was developed using differential equations and was solved in Mathematica® 6.0. The 
analysis was conducted from the perspective of the National payer in Portugal. a 
typical patient enters the model in a given health state, transitions to another health 
state, can develop acquired immunodeﬁ ciency syndrome (AIDS)/ coronary heart 
disease (CHD)/other adverse events or die. Eighteen health states were deﬁ ned based 
on CD4 and HIV RNA levels. We used the maximum likelihood method to estimate 
matrices of instantaneous transition rates corresponding to the efﬁ cacy of the included 
therapies. Six multi-stage treatment strategies depicting clinical practice in Portugal 
were evaluated. The model outputs included projected number of AIDS and CHD 
events, life expectancy and incremental cost-effectiveness ratios (ICER). The model 
was evaluated for internal and external validity and extensive sensitivity analyses were 
conducted. RESULTS: The predicted prevalence of patients in different health states 
over time provided a good ﬁ t to the clinical trial data. Strategies where raltegravir was 
included in the initiating therapy followed by an NNRTI or PI based regimen against 
efavirenz or PI based initiating therapies followed by raltegravir resulted in longer 
undiscounted life expectancy [20.07 Yrs. vs. 18.88 Yrs] and demonstrated cost-
effectiveness [ICERs: c1,078–c33,406/QALY]. CONCLUSIONS: Continuous-time 
Markov modeling based on transition matrices estimated using robust statistical 
methodology is a more realistic and sound approach. Results suggest initiating therapy 
on raltegravir generated lower costs and higher survival versus saving the drug for 
later lines of therapy in Portugal.
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OBJECTIVES: To assess clinical efﬁ cacy and economic effectiveness of Azithromycin 
compared with other antibiotics for community-acquired pneumonia (CAP) and sinus-
itis treatment. METHODS: Decision tree was used to calculate costs of antibiotic 
treatment. The chance nodes included treatment failures and introduction of second-
line therapy or hospitalization. Transition probabilities were obtained from clinical 
trials. Preferred antibiotics for comparison with azithromycin(extended release, 2.0 
g.) and for second-line treatment were chosen by experts in a survey. Medical care 
costs were derived from Moscow mandatory medical insurance system. Costs of the 
medications were obtained from consumer prices database. Sensitivity analysis was 
carried out. RESULTS: Clinical efﬁ cacy was equal. Costs of CAP treatment were 4390 
rub (142.14$) for Amoxycillin and clavulanic acid, 5386 Rub ($174.39) for Cefurox-
ime axetil and 4053 Rub ($131.23) for Azithromycin. Costs of sinusitis treatment 
were 3637(117.76), 3728 (120.71) and 3570 rub ($115,59) for Amoxycillin and 
clavulanic acid, Cefuroxime axetil and Azithromycin respectively. CONCLUSIONS: 
Azithromycin is more efﬁ cient option for CAP and sinusitis treatment than Cefuroxime 
axetil and Amoxycillin and clavulanic acid in Russia.
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OBJECTIVES: To simulate the potential beneﬁ ts of implementing infant vaccination 
with the 10-valent pneumococcal & non-typeable Haemophilus inﬂ uenzae (NTHi)-
protein D conjugate vaccine (PHiD-CV) or the 13-valent pneumococcal conjugate 
vaccine (PCV13) in Latin American countries. METHODS: Vaccine impact was 
assessed using a Markov cohort model for Mexico, Brazil, Chile, and Colombia. The 
model simulates the burden of pneumococcal- and NTHi-related diseases (Invasive 
Disease (ID), Community Acquired Pneumonia (CAP) and Acute Otitis Media (AOM)) 
in a birth cohort followed over a lifetime. Epidemiology, disease management and 
costs are country-speciﬁ c. Vaccination schemes (3 + 1) at 90% coverage & price parity 
were compared to no intervention. Future QALYs and costs discounted at 3.5%, using 
the health care payer perspective are presented. RESULTS: Mortality impact on ID 
and CAP for the two vaccines is projected to be comparable under base-case conditions 
which include minimum assumptions of NTHi infection rates. Vaccines are predicted 
